315239-67-9

Basic information

• Product Name: 1-METHYL-4-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PIPERAZINE
• Synonyms: BUTTPARK 83\09-80;1-METHYL-4-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PIPERAZINE
• CAS NO: 315239-67-9
• Molecular Formula: C₁₂H₁₄F₃N₃O₂
• Molecular Weight: 289.25
• Mol File: 315239-67-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 351.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.326±0.06 g/cm3(Predicted)
• PKA: 7.27±0.42(Predicted)
• CAS DataBase Reference: 1-METHYL-4-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-4-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PIPERAZINE(315239-67-9)
• EPA Substance Registry System: 1-METHYL-4-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PIPERAZINE(315239-67-9)

Safety Data

• Hazardous Substances Data: 315239-67-9(Hazardous Substances Data)

Usage

Chemical class

Piperazine derivatives

Explanation

1-METHYL-4-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PIPERAZINE is a compound that belongs to the class of piperazine derivatives.

Explanation

This piperazine derivative has a specific structure that includes a trifluoromethyl-nitro-phenyl-substituted-phenyl group.

Explanation

The molecular formula of 1-METHYL-4-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PIPERAZINE is C13H15F3N4O2, indicating the number of carbon, hydrogen, fluorine, nitrogen, and oxygen atoms in the compound.

Explanation

The compound is used in the field of medicinal chemistry and pharmaceuticals due to its potential pharmacological properties.

Explanation

1-METHYL-4-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PIPERAZINE may have potential toxic effects, so it is important to handle this chemical compound with caution. It should only be handled by trained professionals in a controlled laboratory setting to ensure safety.

Structural features

Trifluoromethyl-nitro-phenyl-substituted-phenyl group

Application

Medicinal chemistry and pharmaceuticals

Precautions

Potential toxic effects, handling by trained professionals, controlled laboratory setting

Upstream product

• 109-01-3 1-methyl-piperazine 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 

Downstream Products

• 926036-45-5 N-(2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 
• 685853-98-9 2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)aniline 

Relevant articles and documents

Novel pyrazole amide compound and preparation thereof, and application of novel pyrazole amide compound in prevention and treatment of plant pathogenic diseases and pest killing

The invention relates to a novel pyrazole amide compound I and a preparation method thereof and application of the novel pyrazole amide compound I in prevention and treatment of plant pathogenic disease and pest killing. The novel pyrazole amide compound

Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1

ERAP1 is an endoplasmic reticulum-resident zinc aminopeptidase that plays an important role in the immune system by trimming peptides for loading onto major histocompatibility complex proteins. Here, we report discovery of the first inhibitors selective for ERAP1 over its paralogues ERAP2 and IRAP. Compound 1 (N-(N-(2-(1H-indol-3-yl)ethyl)carbamimidoyl)-2,5-difluorobenzenesulfonamide) and compound 2 (1-(1-(4-acetylpiperazine-1-carbonyl)cyclohexyl)-3-(p-tolyl)urea) are competitive inhibitors of ERAP1 aminopeptidase activity. Compound 3 (4-methoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid) allosterically activates ERAP1's hydrolysis of fluorogenic and chromogenic amino acid substrates but competitively inhibits its activity toward a nonamer peptide representative of physiological substrates. Compounds 2 and 3 inhibit antigen presentation in a cellular assay. Compound 3 displays higher potency for an ERAP1 variant associated with increased risk of autoimmune disease. These inhibitors provide mechanistic insights into the determinants of specificity for ERAP1, ERAP2, and IRAP and offer a new therapeutic approach of specifically inhibiting ERAP1 activity in vivo.

PROTEIN KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.